BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES
|
|
- Ginger King
- 5 years ago
- Views:
Transcription
1 BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES IBRAHIM TURKOZ, PhD Janssen Research & Development LLC, NJ BASS XX Nov, 013 BASS XX 1
2 Outline Introduction Background Literature Review Objective Methods EM Algorithm Bayesian Approaches Model Selection Simulations Set-up Results Application Discussions and Conclusions Questions Nov, 013 BASS XX Outline
3 Background Clinical trials can have a major impact on public health Required information for designing a clinical trial is not fully available Ongoing monitoring of accumulating data is necessary Interim analyses are common Usually costly Requires unblinding treatment assignments Statistical implications We will investigate the use of the accumulated data for purposes of modifying aspects of the study design IN BLINDED SETTING Nov, 013 BASS XX Introduction 3
4 Background, Motivating Question, MDD Trial [1] Prior AD Treatment Additional AD Treatment 1. Mahmoud A.R., Pandina J.G., Turkoz I., Kosik-Gonzalez C., Canuso M.C, Kujawa J.M., and Gharabawi G.M. Risperidone for treatment-refractory major depressive disorder. Annals of Internal Medicine, 007; 147: Nov, 013 BASS XX Introduction 4
5 Background, Motivating Question, MDD Trial [1] Active + AD Treatment as usual Prior AD Treatment Additional AD Treatment RANDOMIZATION for those who did not respond Placebo + AD Treatment as usual Placebo + AD Treatment as usual 6 weeks long, but the primary time point was Week 4 1. Mahmoud A.R., Pandina J.G., Turkoz I., Kosik-Gonzalez C., Canuso M.C, Kujawa J.M., and Gharabawi G.M. Risperidone for treatment-refractory major depressive disorder. Annals of Internal Medicine, 007; 147: Nov, 013 BASS XX Introduction 5
6 Background, Motivating Question, MDD Trial [1] Active + AD Treatment as usual Prior AD Treatment Additional AD Treatment RANDOMIZATION for Patients with Caroll Depression Score >0 And CGI-S4 Placebo + AD Treatment as usual Placebo + AD Treatment as usual 6 weeks long, but the primary time point was Week 4 Outcome Parameters Clinician Rated HRSD-17 (primary efficacy scale) CGI-S Patient Reported Most Troubling Symptoms (MTS) or PaRTS-D Patient Global Impression of Severity PGIS 1. Mahmoud A.R., Pandina J.G., Turkoz I., Kosik-Gonzalez C., Canuso M.C, Kujawa J.M., and Gharabawi G.M. Risperidone for treatment-refractory major depressive disorder. Annals of Internal Medicine, 007; 147: Nov, 013 BASS XX Introduction 6
7 Background, Motivating Question, MDD Trial Primary Time Point? Week 4 or Week 6? Primary Endpoint? HRSD-17 or PaRTS-D Nov, 013 BASS XX Introduction 7
8 Background, Motivating Question, Schizoaffective Trial Psychosis Mania Depression Nov, 013 BASS XX Introduction 8
9 Background, Motivating Question, Schizoaffective Trial PANSS Psychosis Mania Depression YMRS 0-60 HAM-D Nov, 013 BASS XX Introduction 9
10 Background, Motivating Question, Schizoaffective Trial [1] Psychosis Mania Depression n=95 PBO Study 300 N=311 n=16 PALI PR 3-1 mg/d (start at 6 mg; flexible) BL Wk 6 1. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR. A randomized, double-blind, placebo-controlled study of dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 010 May;71(5): Nov, 013 BASS XX Introduction 10
11 Background, Motivating Question, Schizoaffective Trial PRIMARY ENDPOINT SECONDARY ENDPOINTS Psychosis Depression HAM-D-1 Changes in PANSS Total Score at Week 6 Mania YMRS Nov, 013 BASS XX Introduction 11
12 Background, Motivating Question, Schizoaffective Trial PRIMARY ENDPOINT SECONDARY ENDPOINTS Psychosis Depression HAM-D-1 Changes in PANSS Total Score at Week 6 FOR REGISTRATION PURPOSES Mania YMRS Nov, 013 BASS XX Introduction 1
13 Background, Motivating Question, Schizoaffective Trial Nov, 013 BASS XX Introduction 13
14 Background, Motivating Question, ADHD Trial 1 1. Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, and Starr HL. Academic, Behavioral, and Cognitive Effects of OROS Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 011 April; 1(): Nov, 013 BASS XX Introduction 14
15 Background, Motivating Question, ADHD Trial 1 1. Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, and Starr HL. Academic, Behavioral, and Cognitive Effects of OROS Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 011 April; 1(): Nov, 013 BASS XX Introduction 15
16 Background It is important to evaluate secondary endpoints to differentiate your drug from other drugs in market place. Nov, 013 BASS XX Introduction 16
17 Background It is important to evaluate secondary endpoints to differentiate your drug from other drugs in market place. Another symptom, Functionality, Medication Satisfaction, Certain Adverse Reactions, Cognition, Etc. Nov, 013 BASS XX Introduction 17
18 Background It is important to evaluate secondary endpoints to differentiate your drug from other drugs in market place Another symptom, Functionality, Medication Satisfaction, Certain Adverse Reactions, Cognition, Etc. Failure to consider important outcomes can limit the conclusions of clinical trials. Nov, 013 BASS XX Introduction 18
19 Background Examination of appropriate statistical methods to test secondary endpoints requires careful consideration Fixed sequence gate-keeping procedures [1,,3,4] are widely used because of their ease of application and interpretation in many circumstances These gate-keeping procedures often require prospective ordering of null hypotheses for secondary endpoints ***Can we use information that is available to order the null hypotheses based on interim effect sizes without breaking the blind? 1. Demitrienko A., Tamhane A., Bretz F. Multiple testing problems in pharmaceutical statistics 010; Chapman&Hall/CRC Biostatistics Series. Westfall P.H., Krishen, A., Optimally weighted, fixed sequence and gatekeeper multiple testing procedure. J of Statistical Planining and Inference. 99 (001) Weins, B., Dmitrienko, A. (005). The fallback procedure for evaluating a single family of hypotheses. Journal of Biopharmaceutical Statistics 15, Bretz F., Maurer W., Brannath W., Posch M., A graphical approach to sequentially rejective multiple test procedures, Stat in Med, 009; 8: Nov, 013 BASS XX Introduction 19
20 Literature Review EM algorithm to estimate the within group variance for sample size reestimation without unblinding at interim stages has been suggested [1,,3] Enrollment order of subjects and the randomization block sizes to estimate the within group variance have also been used [4] Risk of unblinding the treatment effect from blinded inferences based on knowledge of the randomization block size for continuous and binary outcomes [5] The recent draft FDA guidance on adaptive designs [6] discusses possible study design modifications such as selection and/or order of secondary endpoints in addition to sample size re-estimation Blinded treatment effects for survival endpoints [7] were also examined 1.Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics Theory and Methods 199; 1: Shih WJ. Sample size reestimation in clinical trials. In Biopharmaceutical sequential statistical applications, Peace K (ed.). Marcel Dekker: New York, 199; Shih WJ. Sample size reestimation for triple blind clinical trials. Drug Information Journal 1993; 7: Xing B, Ganju J. A method to estimate the variance of an endpoint from an on-going blinded trial. Statistics in Medicine 005; 4: Miller F., Friede T, Kieser T. Blinded assessment of treatment effects utilizing information about randomization block length. Statistics in Medicine 009; 8: Guidance for industry: Adaptive design clinical trials for drugs and biologics Xie J, Quan H, Zhang J. Blinded assessment of treatment effects for survival endpoint in an ongoing trial. Pharmaceutical Statistics 01. Nov, 013 BASS XX Introduction 0
21 Objective Instead of formal interim analyses on unblinded data, use the information from blinded data Assess the feasibility of estimating magnitude of treatment effect on various secondary endpoints in ongoing trial Primary objective is to compare posterior ordering of the signalto-noise ratios (effect sizes), d /, using available data points Nov, 013 BASS XX Introduction 1
22 Model ijk k k ik ik ijk k y 0 z, ~ N(0, ) ii.. d. Y ( i 1,..., n, j 0,1, k 1,,..., K), is the response variable for the k endpoint from j ijk j treatment group on subject i th th Y Y i0k N 0k k i1k ~ N( 1k, k ) ~ (, ) z 0k k ik the mean placebo response magnitude of the treatment effect latent binary treatment assignment We assume that lower 1k 0k k k Y ~ N(, ) y scores are better and the average effect of the treatment is, k Nov, 013 BASS XX Methods
23 Model For a two component univariate normal mixture model, it is appropriate to specify the complete likelihood function for a given response in the form : p( y, z θ) p( y1 θ1) (1 ) p( y0 θ0) ; =p(z 1) 0 0 θ1 1 0 where, θ (, ); (, ); is randomization weight. The signal-to-noise ratio for endpoint k, d /, ( k 1,..., K) k k k ***Our objective is to compare the EM and Bayesian algorithm induced posterior ordering of the signal-to-noise ratios of endpoints, P( d d... d y) 1 k Nov, 013 BASS XX Methods 3
24 EM Algorithm p( y, z θ) p( y θ ) (1 ) p( y θ ) ; =p(z 1) MMLEs are the most common way to estimate parameters of interest; however, MMLEs often do not have closed form solutions. EM seeks the MMLE by iteratively applying Expectation and Maximizing steps. E-Step, E{log p( y, z θ) y, θˆ () t } M-Step, the conditional expectation is maximized with respect to θ. This yields the new estimates ˆ( t1) ( t1) for θ and a distribution for z. Nov, 013 BASS XX Methods 4
25 EM Algorithm Conditional expectation of latent treatment assignment at iteration ( t 1) is: ˆ P( z 1, ) (, ) (1 ) (,. ) () t ( ) ( ) ( 1) () ˆ t ˆ t t ˆ t N( y 0, ) i y θ ( t) ˆ( ) ( ) ( t) ˆ t ˆ t ˆ ˆ ( t) N y 0 N y 0 In the M step, the mean parameters ˆ, ˆ, and variance parameter ˆ at iteration are ( t 1) : 0 n n ( t1) ˆ( t) ( t1) ˆ( t) ( t1) P zi y θ yi P zi y θ yi ˆ 0 ( t1) i 1 ˆ( t1) i 1 0 n n ( t1) ˆ( t) ( t1) ˆ( t) P( zi 0 y, θ ) P( zi 1 y, θ ) i1 i1 ( 0, ) ( 1, )( ) ˆ,, ˆ n (t 1) i1 ( 1, ˆ )( ) ( 0, ˆ P z y θ y P z y θ )( y ) n ( t1) ( t) ( t1) ( t1) ( ) ( t 1) ˆ t ˆ i i 1 i i 0 Nov, 013 BASS XX Methods 5
26 Bayesian Approach The likelihood function of the mixture distribution and the prior distributions of θ and z are combined to obtain the joint posterior distribution, which is assumed to contain all the information about the unknown parameters. Using the Bayes theorem, the posterior distribution satisfies: p( z, θ y) p( y z, θ) p( z θ) p( θ) where, p( y z, θ) is the likelihood pz ( θ) is the prior probability of latent treatment assignment p( θ) is the prior distribution of θ Nov, 013 BASS XX Methods 6
27 Bayesian Approach p( z, θ y) p( y z, θ) p( z θ) p( θ) The conditional distribution of the treatment allocation is proportional : p( z y, θ) p( y z, θ) this reduces to latent treatment allocation probability in EM. Prior Distributions: j ~ N(, ), in order to reduce sensitvity For simplicity purposes, we have 0 ~ N( y0, s0 ), 1 0 N y 1 s1 ~ (, ), Gamma(, ) Nov, 013 BASS XX Methods 7
28 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Nov, 013 BASS XX Methods 8
29 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Likelihood for treatment Nov, 013 BASS XX Methods 9
30 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Likelihood for placebo arm Nov, 013 BASS XX Methods 30
31 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Prior for treatment arm Nov, 013 BASS XX Methods 31
32 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Prior for Placebo arm Nov, 013 BASS XX Methods 3
33 Bayesian Approach Regardless of the structure of the prior distribution, the posterior distribution does not have a simple closed form. In order to make inferences about the unknown parameters, MCMC methodologies are employed to generate samples from the posterior distribution. The joint posterior probability distribution of these parameters satisfies : p( z,,, y) p( y z,,, ) p( z) p(,, ) n 1 1 exp 1 ( y i 0 ) exp ( y i 0) z 1 i zi0 0 y1 0 y0 s1 s0 1 ( ) ( ) 1 exp exp exp( ) Prior for Sigma In computations, =3 and small scale hyperparameter ( 0.01) are assumed. Nov, 013 BASS XX Methods 33
34 BASS XX Bayesian Approach Nov, 013 Methods The posterior conditional distributions of parameters of interest in equation are given by : 1 ~,, ( ) ~ i i i i i i y z y y s s N n n s s s s y z y s N ,, 1 1 ( ) ~ i i i i i i i n z z s s y z
35 Bayesian Approach with Covariate We assume a trial with stratified randomization. The sample is divided into subsamples on the basis of stratifaction factor (covariate: additional medication usage, yes and no groups). Let g i denote the known strata membership of the subject i. g strata and 0 if it does not. The joint posterior distribution then takes the form: i 1 if observation belongs to the yes n 1 1 p( z, 0, yes, no, y) e xp ( y i 0 g ) i zi1 gi0,1 1 ( 0 g y1 ) i g i ( 0 y0) exp ( y i 0) exp exp z 0 0,1 1 i g s s i exp( ) Nov, 013 BASS XX Methods 35
36 Bayesian Approach with Covariate We assume a trial with stratified randomization. The sample is divided into subsamples on the basis of stratifaction factor (covariate: additional medication usage, yes and no groups). Let g i denote the known strata membership of the subject i. g strata and 0 if it does not. The joint posterior distribution then takes the form: i 1 if observation belongs to the yes n 1 1 p( z, 0, yes, no, y) e xp ( y i 0 g ) i zi1 gi0,1 1 ( 0 g y1 ) i g i ( 0 y0) exp ( y i 0) exp exp z 0 0,1 1 i g s s i exp( ) Nov, 013 BASS XX Methods 36
37 Bayesian Approach with Covariate Conditional posterior probability treatment assignment at each iteration is given by : 1 exp ( yi 0 yes ), Yes strata 1 1 exp ( y i 0 yes ) exp ( y i 0) Pz ( i 1) 1 exp ( y i 0 no), No strata 1 1 exp ( yi 0 no) exp ( y i 0) Nov, 013 BASS XX Methods 37
38 Bayesian Approach with Covariate The posterior distribution for parameters of interest are computed to be : yi zi ( yes no) y ( y 0 1, yes yes ) ( y1, no ) no i 1 s0 s1 1 0 ~ N,, n 1 n 1 s0 s1 s0 s 1 yes ~ ( yi 0) zi ( yi 0) zi i1, g 1 0 y 1, yes i1, g 0 y 1, no s N 1 1 s1 1,, no ~ N,, zi zi zi zi i1, g 1 1 i1, g 1 1 i1, g 1 i1, g 1 s1 s 1 s1 s 1 ~ ( yi 0 zi yes ) ( yi 0 zi i1, g 1 i1, g n 3 no ). Nov, 013 BASS XX Methods 38
39 Bayesian Approach with Covariate and a Power Prior Denote the historical data by D approaches no barrowing from D0 0 and current data by D [0,1] to control the influence of the historical data on the current study 1 approaches full barrowing from D [1,,3] The basic idea is to use the power 0 parameter to control the influence of the historical data on the current study Let assume LD ( ) is the past data likelihood 0 LD ( ) is the current data likelihood p D L D p p (, ) ( ) 0 ( ) ( ) is the posterior given past likelihood, Then, the full likelihood is proportional to p( D, ) L( D ) Ibrahim J, Chen MH. Power prior distributions for regression models. Statistical Science 000; 15: Duan Y, Ye K, Smith EP. Evaluating water quality using power priors to incorporate historical information. Environmetrics 006; 17: Hobbs BP, Carlin BP, Mandrekar S, and Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics, 011; 67: Nov, 013 BASS XX Methods 39
40 Bayesian Approach with Covariate and a Power Prior The joint posterior distribution can be extended to include the prior for Think of n 0 0 The result takes the form : as the historical effective sample size. 0 n 1 1 p( z, 0, y, n,, 0 y) exp ( y zi 1 g 1 p, no ( 0 no 1, no) 1 p, no exp s 1 s1 ) 1 n 1 p, yes ( 0 0 yes y1, yes ) n1 p, yes 0 exp ( y i 0) exp s z 0 1 s i 1 n y n n0 p ( 0 0 y0) n0 p 0 exp 1 exp( ) s 0 s0 a1 b1 0 (1 0) Prior for Power Parameter i 0 g Nov, 013 BASS XX Methods 40
41 Bayesian Approach with Covariate and a Power Prior The posterior distribution of parameters of interest is computed to be: 1 a b1 ( 0 0 y0) nop ( 0 yes y1, yes ) n1 p, yes 0 0 (1 0) exp s0 s1 ( 0 0 no y1, no) exp s 1 n 1 p, no 0 yi zi ( yes no) y0n0 p ( y 0 1, yes yes ) n1 p, yes ( y 0 1, no no) n1 p, no ~ i s s N, n n0 p n 0 1p n 0 n 0 p n 0 1p 0 s0 s1 s0 s1 Nov, 013 BASS XX Methods 41
42 Bayesian Approach with Covariate and a Power Prior The posterior distribution of parameters of interest is computed to be: yes no ( yi 0) zi i1, g1 ( 0 y1, yes ) n1 p, yes 0 s 1 1 ~ N,, zi zi i1, g 1 n1 p, yes 0 i1, g 1 n1 p, yes 0 s1 s 1 ~ N i1, g ( y i ) z 0 i ( y ) n 0 1, no 1 p, no s 1 z i i i1, g n1 p, no i1, g n1 p, no s1 s1 Nov, 013 BASS XX Methods ( yi 0 zi yes ) ( yi 0 zi no) i1, g 1 i1, g n 3 ~. 1,, z
43 Model Selection By contrast with frequentist analogues, Bayesian model comparison distinguishes which likelihood and prior combinations better fit the data. These measures of performance can be used to choose a single best model or improve estimation via model averaging. [1] The deviance information criterion (DIC) provides a natural measure of performance in this setting. Models with smaller DIC should be preferred to models with larger DIC. DIC p D, d = D D( θ), since pd D D( θ) = D( ˆ 0, ) D( ˆ 0, ) Expectation over (, ) Expectation over ( ˆ, ˆ ) D.J. Spiegelhalter, N.G. Best, B.P. Carlin, A. Linde. Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistics Society, Series B (Statistical Methodology)00; 64: Nov, 013 BASS XX Methods 43
44 Model Selection 0 ˆ0 ˆ DIC D(, ) D(, ) ( y 0 ) ( 0, ) i zi D E0,, this is a posterior expectation over ( 0, ),average after all the iterations i 1 ˆ ˆ averaged after all the iterations updates at each iteration 0 updates at each iteration z i latent treatment assignment at each iteration ˆ ˆ ( y ˆ0 ) ( ˆ0, ) i zi D Ez, this is a posterior expectation over z, it is using averaged parameters i i i 1 ˆ ˆ 0 averaged after all the iterations ˆ averaged after all the iterations ˆ zi averaged after all the iterations latent treatment assignment at each iteration Nov, 013 BASS XX Methods 44
45 MCMC Gibbs Sampling An important feature of the Gibbs sampler is that each simulated posterior parameter value is always accepted The main drawback of the Gibbs sampler in this setting is the lack of mixing We employed a Metropolis-Hastings algorithm with an acceptance-rejection sampling This involved subsampling 10% of the treatment and placebo group observations and proposing a label switch 1) Draw random candidate samples fromfor switching treatment ) Generate u from the Uniform (0,1) distribution (1 ( pz ( i 1)) i 3) If, u make label change; otherwise return to step 1. pz ( 1) i i Nov, 013 BASS XX Methods 45
46 Simulation Set-Up Scenario d1 d d3 N = 0.5 = > 0.5 > > 0.5 > ~ > 0.5 > ~ > 0.5 > ~0 468 Nov, 013 BASS XX Simulations 46
47 Simulation Set-Up Sample Size and Power Computations using a Two-Sample t-test with Two-Sided Type I Error=0.05 Nov, 013 BASS XX Simulations 47
48 Simulation Set-Up treatment arms with a 1:1 treatment allocation ratio, k 3 uncorrelated endpoints, y, y, and y, 1 3 No missing data, For each case 0 data sets are generated, l ( l 1,...,0), Different prior for each of the endpoints. Scenario d 1 d d = 0.5 = > 0.5 > > 0.5 > > 0.5 > 0 7 N > 0.5 > Generate Input Data Sets: 0( k, l) ~ N( Y0k, s0k), 1 k l 0 k l k l N Y1 k s1k IG k bk k l (, ) (, ) (, ) ~ (, ), ~ (, ), 1,,3, 1,...,0. Without loss of generality, we assumed that 0k 0k 1k Y 10, s s 10 Nov, 013 BASS XX Simulations 48
49 Simulation Set-Up 0 N 1 Each true input clinical trial data set is based on ~ (10,10 ) and with normal distribution with variance 10 and corresponding mean value to generate effect sizes for a given scenario. Initial values of (,, ) for simulations are based on the true input data set parameters and the initial 0 0 power parameter estimate is given as 0.5 and 0.5. Posterior inferences are based on 1000 iterations. The first 00 iterations are considered to be the burn in period for both EM and Bayesian algorithms. th Every 4 point after the burn in period is stored for the Bayesian simulations to reduce correlations to emulate thinning process. Eight hundred simulation results in EM and 00 results in Bayesian methods are summarized. Posterior parameter estimates are summuarized. Empirical probability of each triplet combination of effect size ordering is examined. In each case for a given data set, the last 0 simulation results are kept for effect size orderings. For each of the study data sets, a total of possible triplet combinations of orderings are available. For 0 different study data sets, a total of 160,000 possible orderings are available. Nov, 013 BASS XX Simulations 49
50 Simulation Results Posterior Probability of Effect Size Ordering by Scenario Nov, 013 BASS XX Simulations 50
51 Simulation Results Posterior Distribution of Effect Sizes by Scenario, Averaged Over 0 Data Sets Nov, 013 BASS XX Simulations 51
52 Simulation Results Posterior Distribution of Effect Sizes by Scenario Nov, 013 BASS XX Simulations 5
53 Simulation Results, Scenario 1 Nov, 013 BASS XX Simulations 53
54 Simulation Results, Scenario 1 Nov, 013 BASS XX Simulations 54
55 Simulation Results, Scenario 1 Nov, 013 BASS XX Simulations 55
56 Simulation Results, Scenario 1 Nov, 013 BASS XX Simulations 56
57 Simulation Results, Scenario 1 Nov, 013 BASS XX Simulations 57
58 Simulation Results, Scenario Nov, 013 BASS XX Simulations 58
59 Simulation Results, Scenario Nov, 013 BASS XX Simulations 59
60 Simulation Results, Scenario 3 Nov, 013 BASS XX Simulations 60
61 Simulation Results, Scenario 3 Nov, 013 BASS XX Simulations 61
62 Simulation Results, Scenario 4 Nov, 013 BASS XX Simulations 6
63 Simulation Results, Scenario 4 Nov, 013 BASS XX Simulations 63
64 Simulation Results, Scenario 5 Nov, 013 BASS XX Simulations 64
65 Simulation Results, Scenario 5 Nov, 013 BASS XX Simulations 65
66 MDD Trial Primary Time Point? Week 4 or Week 6? Primary Endpoint? HRSD-17 or PaRTS-D Nov, 013 BASS XX Application 66
67 MDD Trial Results Nov, 013 BASS XX Application 67
68 MDD Trial Results Nov, 013 BASS XX Application 68
69 MDD Study Simulations Decision Rule 1: Calculate the posterior probability that the HRSD 17 effect size at Week 4 is larger than that of Week 6 * * Wk4 Wk6 P( d ( H ) d ( H ) Y) Decision Rule : Calculate 95% Credible Intervals for Week 4 and Week 6 effect sizes Wk4 * Wk 4 Wk 4 Wk6 * Wk6 Wk6 d( H ) d ( H ) d( H ) d( H ) d ( H ) d( H ) Priors for HRSD 17 placebo and treatment means at Week 4 ( H ) were assumed to be : 04 HWk4 N Y0 s0 14( HWk4) ~ N Y1 s1 ( ) ~ ( 15, 7 ), ( 1, 7 ) Wk4 Nov, 013 BASS XX Application 69
70 MDD Study Simulations Summary of Effect Sizes for HRSD-17 and PaRTS-D At Week 4, EM Results were Not Available Posterior Ordering of Effect Sizes for HRSD-17 Week 4 Week 6 EM 0.0% 100.0% Bayesian 47.7% 5.3% Nov, 013 BASS XX Application 70
71 MDD Study Simulations DIC Scores on HRSD-17 and PaRTS-D Nov, 013 BASS XX Application 71
72 Discussion and Conclusion We investigated whether or not the researchers can obtain reliable estimates of effect sizes without knowing treatment assignments. Instead of relying on the clinician s subjective evaluations, the suggested methodologies provide numerical assistance. We showed how to order secondary null hypotheses while the study is ongoing, without unblinding the treatments, without losing the validity of the testing procedure, and with maintaining the integrity of the trial. In our simulations, we used prior distributions whose hyper parameters reflect the true values of the model parameters. In MDD analyses, we used prior distributions whose hyper parameters reflect the original study design elements. Nov, 013 BASS XX Discussion 7
73 Discussion and Conclusion The EM algorithm frequently failed to generate posterior parameter estimates. Both the Bayesian and the EM algorithms overestimated treatment differences and standardized effect sizes. The Bayesian algorithms performed better than existing EM algorithm counterparts in ordering the standardized effect sizes. With the Bayesian algorithm, the posterior probability for identifying the ground-truth ordering increased both as a function of the effect size differences and as a function of the sample size. For large sample sizes, the proportion of times the true ordering was selected was high (above 35%) and the variability of standardized effect sizes was low. With the EM algorithm, the probability for identifying the ground-truth ordering was low (sometimes near zero) and the variability of standardized effect sizes was high. Nov, 013 BASS XX Discussion 73
74 Discussion THANK YOU! QUESTIONS? Nov, 013 BASS XX Discussion 74
Using Historical Experimental Information in the Bayesian Analysis of Reproduction Toxicological Experimental Results
Using Historical Experimental Information in the Bayesian Analysis of Reproduction Toxicological Experimental Results Jing Zhang Miami University August 12, 2014 Jing Zhang (Miami University) Using Historical
More informationTesting a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials
Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in
More informationSuperchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation
August 01, 2012 Disclaimer: This presentation reflects the views of the author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration Introduction We describe
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,
More informationAdaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013
Adaptive designs beyond p-value combination methods Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Outline Introduction Combination-p-value method and conditional error function
More informationTwo-stage Adaptive Randomization for Delayed Response in Clinical Trials
Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Guosheng Yin Department of Statistics and Actuarial Science The University of Hong Kong Joint work with J. Xu PSI and RSS Journal
More informationAdaptive Dunnett Tests for Treatment Selection
s for Treatment Selection Franz König 1 Werner Brannath 1 Frank Bretz 2 Martin Posch 1 1 Section of Medical Statistics Medical University of Vienna 2 Novartis Pharma AG Basel Workshop Adaptive Designs
More informationOn Generalized Fixed Sequence Procedures for Controlling the FWER
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 On Generalized Fixed Sequence Procedures for Controlling the FWER Zhiying Qiu, a Wenge Guo b and Gavin Lynch c Testing
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationA Clinical Trial Simulation System, Its Applications, and Future Challenges. Peter Westfall, Texas Tech University Kuenhi Tsai, Merck Research Lab
A Clinical Trial Simulation System, Its Applications, and Future Challenges Peter Westfall, Texas Tech University Kuenhi Tsai, Merck Research Lab Acknowledgement Major collaborators Stephan Ogenstand,
More informationThe Design of Group Sequential Clinical Trials that Test Multiple Endpoints
The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull
More informationType I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University
More informationAn extrapolation framework to specify requirements for drug development in children
An framework to specify requirements for drug development in children Martin Posch joint work with Gerald Hlavin Franz König Christoph Male Peter Bauer Medical University of Vienna Clinical Trials in Small
More informationSample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018
Sample Size Re-estimation in Clinical Trials: Dealing with those unknowns Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj University of Kyoto,
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationBayesian methods for sample size determination and their use in clinical trials
Bayesian methods for sample size determination and their use in clinical trials Stefania Gubbiotti Abstract This paper deals with determination of a sample size that guarantees the success of a trial.
More informationA Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications
A Mixture Gatekeeping Procedure Based on the Hommel Test for Clinical Trial Applications Thomas Brechenmacher (Dainippon Sumitomo Pharma Co., Ltd.) Jane Xu (Sunovion Pharmaceuticals Inc.) Alex Dmitrienko
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationAdaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests.
1/35 Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. Martin Posch Center for Medical Statistics, Informatics and Intelligent Systems Medical University
More informationCTDL-Positive Stable Frailty Model
CTDL-Positive Stable Frailty Model M. Blagojevic 1, G. MacKenzie 2 1 Department of Mathematics, Keele University, Staffordshire ST5 5BG,UK and 2 Centre of Biostatistics, University of Limerick, Ireland
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationComparison of Three Calculation Methods for a Bayesian Inference of Two Poisson Parameters
Journal of Modern Applied Statistical Methods Volume 13 Issue 1 Article 26 5-1-2014 Comparison of Three Calculation Methods for a Bayesian Inference of Two Poisson Parameters Yohei Kawasaki Tokyo University
More informationeqr094: Hierarchical MCMC for Bayesian System Reliability
eqr094: Hierarchical MCMC for Bayesian System Reliability Alyson G. Wilson Statistical Sciences Group, Los Alamos National Laboratory P.O. Box 1663, MS F600 Los Alamos, NM 87545 USA Phone: 505-667-9167
More informationBayesian Linear Models
Bayesian Linear Models Sudipto Banerjee 1 and Andrew O. Finley 2 1 Department of Forestry & Department of Geography, Michigan State University, Lansing Michigan, U.S.A. 2 Biostatistics, School of Public
More informationBayesian Methods for Machine Learning
Bayesian Methods for Machine Learning CS 584: Big Data Analytics Material adapted from Radford Neal s tutorial (http://ftp.cs.utoronto.ca/pub/radford/bayes-tut.pdf), Zoubin Ghahramni (http://hunch.net/~coms-4771/zoubin_ghahramani_bayesian_learning.pdf),
More informationModel Selection in Bayesian Survival Analysis for a Multi-country Cluster Randomized Trial
Model Selection in Bayesian Survival Analysis for a Multi-country Cluster Randomized Trial Jin Kyung Park International Vaccine Institute Min Woo Chae Seoul National University R. Leon Ochiai International
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationAdaptive Treatment Selection with Survival Endpoints
Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,
More informationBayesian concept for combined Phase 2a/b trials
Bayesian concept for combined Phase 2a/b trials /////////// Stefan Klein 07/12/2018 Agenda Phase 2a: PoC studies Phase 2b: dose finding studies Simulation Results / Discussion 2 /// Bayer /// Bayesian
More informationA Bayesian multi-dimensional couple-based latent risk model for infertility
A Bayesian multi-dimensional couple-based latent risk model for infertility Zhen Chen, Ph.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health
More informationBayesian Linear Models
Bayesian Linear Models Sudipto Banerjee 1 and Andrew O. Finley 2 1 Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, U.S.A. 2 Department of Forestry & Department
More informationGlobal Sensitivity Analysis for Repeated Measures Studies with Informative Drop-out: A Semi-Parametric Approach
Global for Repeated Measures Studies with Informative Drop-out: A Semi-Parametric Approach Daniel Aidan McDermott Ivan Diaz Johns Hopkins University Ibrahim Turkoz Janssen Research and Development September
More informationDose-response modeling with bivariate binary data under model uncertainty
Dose-response modeling with bivariate binary data under model uncertainty Bernhard Klingenberg 1 1 Department of Mathematics and Statistics, Williams College, Williamstown, MA, 01267 and Institute of Statistics,
More informationIntroduction to Bayesian Statistics and Markov Chain Monte Carlo Estimation. EPSY 905: Multivariate Analysis Spring 2016 Lecture #10: April 6, 2016
Introduction to Bayesian Statistics and Markov Chain Monte Carlo Estimation EPSY 905: Multivariate Analysis Spring 2016 Lecture #10: April 6, 2016 EPSY 905: Intro to Bayesian and MCMC Today s Class An
More informationBayesian Meta-analysis with Hierarchical Modeling Brian P. Hobbs 1
Bayesian Meta-analysis with Hierarchical Modeling Brian P. Hobbs 1 Division of Biostatistics, School of Public Health, University of Minnesota, Mayo Mail Code 303, Minneapolis, Minnesota 55455 0392, U.S.A.
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationBayesian model selection for computer model validation via mixture model estimation
Bayesian model selection for computer model validation via mixture model estimation Kaniav Kamary ATER, CNAM Joint work with É. Parent, P. Barbillon, M. Keller and N. Bousquet Outline Computer model validation
More informationMarkov Chain Monte Carlo methods
Markov Chain Monte Carlo methods By Oleg Makhnin 1 Introduction a b c M = d e f g h i 0 f(x)dx 1.1 Motivation 1.1.1 Just here Supresses numbering 1.1.2 After this 1.2 Literature 2 Method 2.1 New math As
More informationPrinciples of Bayesian Inference
Principles of Bayesian Inference Sudipto Banerjee University of Minnesota July 20th, 2008 1 Bayesian Principles Classical statistics: model parameters are fixed and unknown. A Bayesian thinks of parameters
More informationMULTISTAGE AND MIXTURE PARALLEL GATEKEEPING PROCEDURES IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 21: 726 747, 2011 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543406.2011.551333 MULTISTAGE AND MIXTURE PARALLEL
More information2015 Duke-Industry Statistics Symposium. Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data
2015 Duke-Industry Statistics Symposium Sample Size Determination for a Three-arm Equivalence Trial of Poisson and Negative Binomial Data Victoria Chang Senior Statistician Biometrics and Data Management
More informationBlinded sample size reestimation with count data
Blinded sample size reestimation with count data Tim Friede 1 and Heinz Schmidli 2 1 Universtiy Medical Center Göttingen, Germany 2 Novartis Pharma AG, Basel, Switzerland BBS Early Spring Conference 2010
More informationBayesian Inference in GLMs. Frequentists typically base inferences on MLEs, asymptotic confidence
Bayesian Inference in GLMs Frequentists typically base inferences on MLEs, asymptotic confidence limits, and log-likelihood ratio tests Bayesians base inferences on the posterior distribution of the unknowns
More informationPart 6: Multivariate Normal and Linear Models
Part 6: Multivariate Normal and Linear Models 1 Multiple measurements Up until now all of our statistical models have been univariate models models for a single measurement on each member of a sample of
More informationAssessing the Effect of Prior Distribution Assumption on the Variance Parameters in Evaluating Bioequivalence Trials
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 8--006 Assessing the Effect of Prior Distribution Assumption on the Variance
More informationSAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 18: 1184 1196, 2008 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400802369053 SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE
More informationDivision of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series
Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Year: 2013 #006 The Expected Value of Information in Prospective Drug Safety Monitoring Jessica M. Franklin a, Amanda R. Patrick
More informationBios 6649: Clinical Trials - Statistical Design and Monitoring
Bios 6649: Clinical Trials - Statistical Design and Monitoring Spring Semester 2015 John M. Kittelson Department of Biostatistics & nformatics Colorado School of Public Health University of Colorado Denver
More informationMixtures of multiple testing procedures for gatekeeping applications in clinical trials
Research Article Received 29 January 2010, Accepted 26 May 2010 Published online 18 April 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.4008 Mixtures of multiple testing procedures
More informationFrailty Modeling for Spatially Correlated Survival Data, with Application to Infant Mortality in Minnesota By: Sudipto Banerjee, Mela. P.
Frailty Modeling for Spatially Correlated Survival Data, with Application to Infant Mortality in Minnesota By: Sudipto Banerjee, Melanie M. Wall, Bradley P. Carlin November 24, 2014 Outlines of the talk
More informationThe Jackknife-Like Method for Assessing Uncertainty of Point Estimates for Bayesian Estimation in a Finite Gaussian Mixture Model
Thai Journal of Mathematics : 45 58 Special Issue: Annual Meeting in Mathematics 207 http://thaijmath.in.cmu.ac.th ISSN 686-0209 The Jackknife-Like Method for Assessing Uncertainty of Point Estimates for
More informationStat 542: Item Response Theory Modeling Using The Extended Rank Likelihood
Stat 542: Item Response Theory Modeling Using The Extended Rank Likelihood Jonathan Gruhl March 18, 2010 1 Introduction Researchers commonly apply item response theory (IRT) models to binary and ordinal
More informationPower and Sample Size Calculations with the Additive Hazards Model
Journal of Data Science 10(2012), 143-155 Power and Sample Size Calculations with the Additive Hazards Model Ling Chen, Chengjie Xiong, J. Philip Miller and Feng Gao Washington University School of Medicine
More information7. Estimation and hypothesis testing. Objective. Recommended reading
7. Estimation and hypothesis testing Objective In this chapter, we show how the election of estimators can be represented as a decision problem. Secondly, we consider the problem of hypothesis testing
More informationUse of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children
Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children Lisa Hampson, Franz Koenig and Martin Posch Department of Mathematics
More informationBayesian non-parametric model to longitudinally predict churn
Bayesian non-parametric model to longitudinally predict churn Bruno Scarpa Università di Padova Conference of European Statistics Stakeholders Methodologists, Producers and Users of European Statistics
More informationMarkov Chain Monte Carlo in Practice
Markov Chain Monte Carlo in Practice Edited by W.R. Gilks Medical Research Council Biostatistics Unit Cambridge UK S. Richardson French National Institute for Health and Medical Research Vilejuif France
More informationEstimation in Flexible Adaptive Designs
Estimation in Flexible Adaptive Designs Werner Brannath Section of Medical Statistics Core Unit for Medical Statistics and Informatics Medical University of Vienna BBS and EFSPI Scientific Seminar on Adaptive
More informationSurvival Analysis for Case-Cohort Studies
Survival Analysis for ase-ohort Studies Petr Klášterecký Dept. of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, harles University, Prague, zech Republic e-mail: petr.klasterecky@matfyz.cz
More informationBayesian Hypothesis Testing in GLMs: One-Sided and Ordered Alternatives. 1(w i = h + 1)β h + ɛ i,
Bayesian Hypothesis Testing in GLMs: One-Sided and Ordered Alternatives Often interest may focus on comparing a null hypothesis of no difference between groups to an ordered restricted alternative. For
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More informationCase Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial William R. Gillespie Pharsight Corporation Cary, North Carolina, USA PAGE 2003 Verona,
More informationSTA 4273H: Statistical Machine Learning
STA 4273H: Statistical Machine Learning Russ Salakhutdinov Department of Computer Science! Department of Statistical Sciences! rsalakhu@cs.toronto.edu! h0p://www.cs.utoronto.ca/~rsalakhu/ Lecture 7 Approximate
More informationPlausible Values for Latent Variables Using Mplus
Plausible Values for Latent Variables Using Mplus Tihomir Asparouhov and Bengt Muthén August 21, 2010 1 1 Introduction Plausible values are imputed values for latent variables. All latent variables can
More informationMaking rating curves - the Bayesian approach
Making rating curves - the Bayesian approach Rating curves what is wanted? A best estimate of the relationship between stage and discharge at a given place in a river. The relationship should be on the
More informationMachine Learning. Gaussian Mixture Models. Zhiyao Duan & Bryan Pardo, Machine Learning: EECS 349 Fall
Machine Learning Gaussian Mixture Models Zhiyao Duan & Bryan Pardo, Machine Learning: EECS 349 Fall 2012 1 The Generative Model POV We think of the data as being generated from some process. We assume
More informationBayesian Linear Regression
Bayesian Linear Regression Sudipto Banerjee 1 Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, U.S.A. September 15, 2010 1 Linear regression models: a Bayesian perspective
More informationThe Particle Filter. PD Dr. Rudolph Triebel Computer Vision Group. Machine Learning for Computer Vision
The Particle Filter Non-parametric implementation of Bayes filter Represents the belief (posterior) random state samples. by a set of This representation is approximate. Can represent distributions that
More informationA Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks
A Gatekeeping Test in a Group Sequential Design 1 A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks Ajit C. Tamhane Department of Industrial
More informationDownloaded from:
Camacho, A; Kucharski, AJ; Funk, S; Breman, J; Piot, P; Edmunds, WJ (2014) Potential for large outbreaks of Ebola virus disease. Epidemics, 9. pp. 70-8. ISSN 1755-4365 DOI: https://doi.org/10.1016/j.epidem.2014.09.003
More informationEvidence synthesis for a single randomized controlled trial and observational data in small populations
Evidence synthesis for a single randomized controlled trial and observational data in small populations Steffen Unkel, Christian Röver and Tim Friede Department of Medical Statistics University Medical
More informationBonferroni - based gatekeeping procedure with retesting option
Bonferroni - based gatekeeping procedure with retesting option Zhiying Qiu Biostatistics and Programming, Sanofi Bridgewater, NJ 08807, U.S.A. Wenge Guo Department of Mathematical Sciences New Jersey Institute
More informationEvaluating the value of structural heath monitoring with longitudinal performance indicators and hazard functions using Bayesian dynamic predictions
Evaluating the value of structural heath monitoring with longitudinal performance indicators and hazard functions using Bayesian dynamic predictions C. Xing, R. Caspeele, L. Taerwe Ghent University, Department
More informationGroup Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,
More informationAdaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.100/sim.0000 Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample
More informationROI ANALYSIS OF PHARMAFMRI DATA:
ROI ANALYSIS OF PHARMAFMRI DATA: AN ADAPTIVE APPROACH FOR GLOBAL TESTING Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Department of Statistics and Warwick Centre of Analytical Sciences,
More informationPractical considerations for survival models
Including historical data in the analysis of clinical trials using the modified power prior Practical considerations for survival models David Dejardin 1 2, Joost van Rosmalen 3 and Emmanuel Lesaffre 1
More informationThe STS Surgeon Composite Technical Appendix
The STS Surgeon Composite Technical Appendix Overview Surgeon-specific risk-adjusted operative operative mortality and major complication rates were estimated using a bivariate random-effects logistic
More informationDIC: Deviance Information Criterion
(((( Welcome Page Latest News DIC: Deviance Information Criterion Contact us/bugs list WinBUGS New WinBUGS examples FAQs DIC GeoBUGS DIC (Deviance Information Criterion) is a Bayesian method for model
More informationUniformly Most Powerful Bayesian Tests and Standards for Statistical Evidence
Uniformly Most Powerful Bayesian Tests and Standards for Statistical Evidence Valen E. Johnson Texas A&M University February 27, 2014 Valen E. Johnson Texas A&M University Uniformly most powerful Bayes
More informationIncluding historical data in the analysis of clinical trials using the modified power priors: theoretical overview and sampling algorithms
Including historical data in the analysis of clinical trials using the modified power priors: theoretical overview and sampling algorithms Joost van Rosmalen 1, David Dejardin 2,3, and Emmanuel Lesaffre
More informationNon-Parametric Bayes
Non-Parametric Bayes Mark Schmidt UBC Machine Learning Reading Group January 2016 Current Hot Topics in Machine Learning Bayesian learning includes: Gaussian processes. Approximate inference. Bayesian
More informationA simulation study for comparing testing statistics in response-adaptive randomization
RESEARCH ARTICLE Open Access A simulation study for comparing testing statistics in response-adaptive randomization Xuemin Gu 1, J Jack Lee 2* Abstract Background: Response-adaptive randomizations are
More informationStepwise Gatekeeping Procedures in Clinical Trial Applications
984 Biometrical Journal 48 (2006) 6, 984 991 DOI: 10.1002/bimj.200610274 Stepwise Gatekeeping Procedures in Clinical Trial Applications Alex Dmitrienko *,1, Ajit C. Tamhane 2, Xin Wang 2, and Xun Chen
More informationComputer Vision Group Prof. Daniel Cremers. 10a. Markov Chain Monte Carlo
Group Prof. Daniel Cremers 10a. Markov Chain Monte Carlo Markov Chain Monte Carlo In high-dimensional spaces, rejection sampling and importance sampling are very inefficient An alternative is Markov Chain
More informationLecture 9: Learning Optimal Dynamic Treatment Regimes. Donglin Zeng, Department of Biostatistics, University of North Carolina
Lecture 9: Learning Optimal Dynamic Treatment Regimes Introduction Refresh: Dynamic Treatment Regimes (DTRs) DTRs: sequential decision rules, tailored at each stage by patients time-varying features and
More informationMarkov Chain Monte Carlo
Markov Chain Monte Carlo Recall: To compute the expectation E ( h(y ) ) we use the approximation E(h(Y )) 1 n n h(y ) t=1 with Y (1),..., Y (n) h(y). Thus our aim is to sample Y (1),..., Y (n) from f(y).
More informationA Bayesian Nonparametric Approach to Monotone Missing Data in Longitudinal Studies with Informative Missingness
A Bayesian Nonparametric Approach to Monotone Missing Data in Longitudinal Studies with Informative Missingness A. Linero and M. Daniels UF, UT-Austin SRC 2014, Galveston, TX 1 Background 2 Working model
More informationBayesian data analysis in practice: Three simple examples
Bayesian data analysis in practice: Three simple examples Martin P. Tingley Introduction These notes cover three examples I presented at Climatea on 5 October 0. Matlab code is available by request to
More informationPart 7: Hierarchical Modeling
Part 7: Hierarchical Modeling!1 Nested data It is common for data to be nested: i.e., observations on subjects are organized by a hierarchy Such data are often called hierarchical or multilevel For example,
More informationOn the efficiency of two-stage adaptive designs
On the efficiency of two-stage adaptive designs Björn Bornkamp (Novartis Pharma AG) Based on: Dette, H., Bornkamp, B. and Bretz F. (2010): On the efficiency of adaptive designs www.statistik.tu-dortmund.de/sfb823-dp2010.html
More informationHealth utilities' affect you are reported alongside underestimates of uncertainty
Dr. Kelvin Chan, Medical Oncologist, Associate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre and Dr. Eleanor Pullenayegum, Senior Scientist, Hospital for Sick Children Title: Underestimation
More informationMCMC algorithms for fitting Bayesian models
MCMC algorithms for fitting Bayesian models p. 1/1 MCMC algorithms for fitting Bayesian models Sudipto Banerjee sudiptob@biostat.umn.edu University of Minnesota MCMC algorithms for fitting Bayesian models
More informationStudy Notes on the Latent Dirichlet Allocation
Study Notes on the Latent Dirichlet Allocation Xugang Ye 1. Model Framework A word is an element of dictionary {1,,}. A document is represented by a sequence of words: =(,, ), {1,,}. A corpus is a collection
More informationPetr Volf. Model for Difference of Two Series of Poisson-like Count Data
Petr Volf Institute of Information Theory and Automation Academy of Sciences of the Czech Republic Pod vodárenskou věží 4, 182 8 Praha 8 e-mail: volf@utia.cas.cz Model for Difference of Two Series of Poisson-like
More informationMarkov Chain Monte Carlo methods
Markov Chain Monte Carlo methods Tomas McKelvey and Lennart Svensson Signal Processing Group Department of Signals and Systems Chalmers University of Technology, Sweden November 26, 2012 Today s learning
More informationIntroduction to Markov Chain Monte Carlo & Gibbs Sampling
Introduction to Markov Chain Monte Carlo & Gibbs Sampling Prof. Nicholas Zabaras Sibley School of Mechanical and Aerospace Engineering 101 Frank H. T. Rhodes Hall Ithaca, NY 14853-3801 Email: zabaras@cornell.edu
More informationBayesian Inference on Joint Mixture Models for Survival-Longitudinal Data with Multiple Features. Yangxin Huang
Bayesian Inference on Joint Mixture Models for Survival-Longitudinal Data with Multiple Features Yangxin Huang Department of Epidemiology and Biostatistics, COPH, USF, Tampa, FL yhuang@health.usf.edu January
More informationGroup sequential designs with negative binomial data
Group sequential designs with negative binomial data Ekkehard Glimm 1 Tobias Mütze 2,3 1 Statistical Methodology, Novartis, Basel, Switzerland 2 Department of Medical Statistics, University Medical Center
More informationImproving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates
Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates Anastasios (Butch) Tsiatis Department of Statistics North Carolina State University http://www.stat.ncsu.edu/
More information